Binnopharm Group's export revenue in 2024 reached ₽3.8 billion. The main contribution to this growth was made by key markets - Kazakhstan, Kyrgyzstan and Uzbekistan, where the volume of supplies increased by 30%. This was possible due to successful registration of new drugs and portfolio expansion, as well as active promotion and interaction with the medical community, the company notes. In 2024, Binnopharm Group received 68 registration certificates for 22 drugs. Documents have been approved in 11 countries.